INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 45h ago
HOUSE PTR5h ago
SEC 13F5h ago
ROBINHOOD CHAIN5h ago
SEC FORM 4/Disposition to issuerVerified data

Backstrom Jay T. reported LVTX

Director · LAVA Therapeutics NV · LAVA Therapeutics NV — Share Options (Right to Buy)

Side
D
Value
—
Shares
33.4K
Price
—
Executed
Nov 13, 2025
Disclosed
Nov 17, 2025
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Nov 13 executedNov 17, 2025 disclosed

LVTX · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Disposition to issuer — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · LVTX

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    WE
    Wadlinger Mary E.Director
    LVTXLAVA Therapeutics NV
    Disposition to issuer
    		D—
    33.4K sh
    		Nov 13, 2025Nov 17, 2025
    traded Nov 13, 2025
    		+4dSEC FORM 4

    Evidence

    9
    OJ
    Oliger Christy J.Director
    LVTXLAVA Therapeutics NV
    Disposition to issuer
    		D—
    33.4K sh
    		Nov 13, 2025Nov 17, 2025
    traded Nov 13, 2025
    		+4dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001796398-25-000004
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Nov 13, 2025
    Published
    Nov 17, 2025
    Ingested by INSIDER
    Nov 5, 04:32 UTC
    Last re-read
    Nov 5, 04:32 UTC

    Extracted facts

    Filer
    Backstrom Jay T.
    Role
    Director
    Transaction
    Disposition to issuerAs filed: “D”
    Asset
    LAVA Therapeutics NV — Share Options (Right to Buy)
    Ticker
    LVTX
    Shares
    33.4K
    Price per share
    $0
    Execution date (reported)
    Nov 13, 2025
    Owned after transaction
    0 shares
    Days from execution to publication
    4

    What this establishes

    Backstrom Jay T. filed this Form 4 reporting a disposition to issuer of LVTX on Nov 13, 2025. It became public on Nov 17, 2025. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director
    Backstrom Jay T.cik:0001796398
    Issuer
    LAVA Therapeutics NVcik:0001840748

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.

    Source error

    Price history for LVTX is unavailable.

    An error occurred in the Server Components render. The specific message is omitted in production builds to avoid leaking sensitive details. A digest property is included on this error instance which may provide additional details about the nature of the error.